Additionally, in vivo studies for acute myeloid leukemia (AML), cytokine release syndrome (CRS), and coxsackie virus B have suggested mir-146a as a potential therapeutic agent targeting the NF-kB-signaling pathway and the consecutive release of IL-1 and IL-6 inflammatory cytokines. Here, IL6 is linked to congenital rubella syndrome.